Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

176
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
176
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

139
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
139
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

280
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
280
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

23
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
23
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual perspectives: a narrative case study on a medical student's utilization of library resources as a medical library assistant.

Medical reference services quarterly·2026
Same author

Role of Liver Function Assessment in Portal Venous Interventions and Locoregional Therapies for Liver Tumors.

Techniques in vascular and interventional radiology·2025
Same author

Artificial Intelligence Applications in the Diagnosis and Management of Cirrhosis and Portal Hypertension: A Narrative Review.

Techniques in vascular and interventional radiology·2025
Same author

Liver Augmentation: Rationale, Current Status, and Future Directions.

Techniques in vascular and interventional radiology·2025
Same author

Chronic Portal Vein Thrombosis: Diagnosis, Management, and Review of the Literature.

Techniques in vascular and interventional radiology·2025
Same author

Management of Portal Hypertension in Oncologic Patients.

Techniques in vascular and interventional radiology·2025

Related Experiment Video

Updated: Sep 12, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

697

Post-TIPS Encephalopathy: Clinical Presentation, Diagnosis, and Management.

Doo Hee Kim1, Hassan Anbari2, Sameer Gadani3

  • 1Department of Radiology, MedStar Georgetown University Hospital, Washington, DC.

Techniques in Vascular and Interventional Radiology
|August 10, 2025
PubMed
Summary

Transjugular intrahepatic portosystemic shunt (TIPS) creation can lead to hepatic encephalopathy (HE). This study details patient and procedural factors increasing HE risk after TIPS and discusses its management.

Keywords:
EncephalopathyEndovascularTIPS revision

More Related Videos

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

2.9K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.3K

Related Experiment Videos

Last Updated: Sep 12, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

697
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

2.9K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.3K

Area of Science:

  • Hepatology
  • Interventional Radiology
  • Gastroenterology

Background:

  • Portal hypertension management often involves Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation.
  • Hepatic Encephalopathy (HE) remains a significant complication post-TIPS.
  • Understanding risk factors for post-TIPS HE is crucial for patient care.

Purpose of the Study:

  • To identify clinical and procedural factors associated with the development of hepatic encephalopathy after TIPS placement.
  • To provide a comprehensive overview of managing patients experiencing hepatic encephalopathy post-TIPS.

Main Methods:

  • Review of patient clinical conditions and TIPS creation parameters.
  • Analysis of factors contributing to the likelihood of post-TIPS hepatic encephalopathy.
  • Discussion of current management strategies for post-TIPS hepatic encephalopathy.

Main Results:

  • Several patient-specific and procedural factors are identified as increasing the risk of hepatic encephalopathy following TIPS.
  • Detailed insights into the multifactorial nature of post-TIPS HE are presented.

Conclusions:

  • Identifying and mitigating pre-procedural risk factors can potentially reduce the incidence of hepatic encephalopathy after TIPS.
  • Effective management strategies are essential for patients who develop hepatic encephalopathy post-TIPS.